Biosimilar medicines - Their use in the treatment of inflammatory bowel diseases. Position statement of the Working Group of the Polish National Consultant in Gastroenterology

Przeglad Gastroenterologiczny

Volumn 9, Issue 1, 2014, Pages 1-3

  Mularczyk, Aldona ^a   Gonciarz, Maciej ^a   Bartnik, Witold ^b   Durlik, Marek ^c,d   Eder, Piotr ^e   Ga̧siorowska, Anita ^f   Linke, Krzysztof ^e   Łodyga, Michał ^d   Łykowska Szuber, Liliana ^e   Małecka Panas, Ewa ^f   Pawlik, Magdalena ^d   Radwan, Piotr ^g   Rydzewska, Grazyna ^d,h  

^a St Barbara's Main District Hospital   (Poland)

^b INSTITUTE OF ONCOLOGY   (Poland)

^c MOSSAKOWSKI MEDICAL RESEARCH CENTRE   (Poland)

^d CENTRAL CLINICAL HOSPITAL   (Poland)

^e POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

^f MEDICAL UNIVERSITY OF LODZ   (Poland)

^g MEDICAL UNIVERSITY OF LUBLIN   (Poland)

^h JAN KOCHANOWSKI UNIVERSITY   (Poland)

Author keywords

Biosimilar medicines; Inflammatory bowel disease

Indexed keywords

BIOSIMILAR AGENT;

ARTICLE; DRUG USE; GASTROENTEROLOGY; INFLAMMATORY BOWEL DISEASE; MEDICAL SOCIETY; MEDICAL SPECIALIST; POLAND; PRACTICE GUIDELINE;

EID: 84896273663     PISSN: 18955770     EISSN: 18974317     Source Type: Journal    
DOI: 10.5114/pg.2014.40842     Document Type: Article

References (11)

1. Walsh G. Second-generation biopharmaceuticals. Eur J Pharm Biopharm 2004; 58: 185-96. (Pubitemid 39037228)
2. Available at: http://www.pharma.org/files/Biotech%202006.pdf/
3. Wang J, Chow SC. On the regulatory approval pathway of biosimilar products. Pharmaceuticals 2012; 5: 353-68.
4. Lee JF, Litten JB, Grampp G. Comparabillity and biosimilarity: considerations for the healthcare provider. Curr Med Res Opin 2012; 28: 1053-8.
5. Schneider CK. Biosimilars in rheumatology: the wind of change. Ann Rheum Dis 2013; 72: 315-8.
6. European Medicines Agency. Questions and answers on biosimilar medicines (similar biological medicinal products). http://www.ema.europa.eu/docs/en-GB/ document-library/Medicine-QA/2009/12/WC500020062.pdf/.
7. European Medicines Agency. Summary of opinion (initial authorisation) Remsima(infliximab).http://www.ema.europa.eu/docs/en-GB/document- library/Summary-of-opinion-Initial-authorisation/human/002576/WC500144832.pdf/.
8. Yoo DH, Hrycaj P, Miranda P, et al. A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study. Ann Rheum Dis 2013; 72: 1613-20.
9. Maini R, St Clair EW, Breedveld F, et al. Infliximab (chimeric antitumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet 1999; 354: 1932-9.
10. Park W, Hrycaj P, Jeka S, et al. A randomised, double-blind, multicenter paralel - group, prospective study comparing pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study. Ann Rheum Dis 2013; 72: 1605-12.
11. Danese S, Gomollon F. ECCO position statement: the use of biosimilar medicines in the treatment of inflammatory bowel disease (IBD). J Crohns Colitis 2013; 7: 586-9.